MCM8-MCM9 Complex as A Potential Drug Target (P48169)
MCM8-MCM9 Complex as A Potential Drug Target
The MCM8-MCM9 complex is a protein complex that is found in the endoplasmic reticulum (ER) and is involved in the regulation of protein stability and localization in the cell. The MCM8-MCM9 complex consists of two subunits, MCM8 and MCM9, which are both involved in the same process of protein localization.
MCM8 is a 23-kDa protein that is composed of a unique nucleotide-binding oligomeric domain and a transmembrane region. MCM8 is the protein that is targeted by the therapeutic drug N-acetylmethionine (NAM), which is an inhibitor of the enzyme homocysteine 鈥嬧??( Hcyt) thiolation reaction in the error-correcting modification pathway. By binding to NAM, the activity of MCM8 is inhibited, resulting in a decrease in Hcyt activity, which in turn leads to a decrease in the stability of the protein within the cell.
MCM9 is a 26-kDa protein that is composed of a nucleotide-binding oligomeric domain and a cytoplasmic tail. MCM9 is involved in the regulation of protein stability and localization in the cell. It plays a role in the negative regulation of MCM8, by preventing MCM8 from being processed and degraded.
The MCM8-MCM9 complex is a protein that has been identified as a potential drug target in the context of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The reason for this is the ability of the MCM8-MCM9 complex to regulate the stability and localization of proteins in the cell, which can lead to the dysfunction of various cellular processes and the development of diseases.
One of the potential strategies to target the MCM8-MCM9 complex is to inhibit the activity of NAM, which is known to be a potent inhibitor of thiolation reactions in the Hcyt error-correcting modification pathway. By inhibiting the activity of NAM, the MCM8-MCM9 complex would be able to function normally and the levels of MCM8 in the ER would be stabilized.
Another approach to target the MCM8-MCM9 complex is to inhibit the transport of MCM9 to the ER, which would result in the accumulation of MCM9 in the ER and the disruption of the MCM8-MCM9 complex. This would result in the levels of MCM8 in the ER being stabilized and the activity of MCM9 being inhibited.
In addition to these strategies, there are also several research studies that have investigated the potential targets of the MCM8-MCM9 complex. For example, researchers have found that the MCM8-MCM9 complex is involved in the regulation of protein stability and localization in various diseases , including cancer, neurodegenerative diseases, and autoimmune diseases.
Overall, the MCM8-MCM9 complex is a protein that has the potential to be a drug target or biomarker in various diseases. The inhibition of the activity of NAM and the transport of MCM9 to the ER are two potential strategies for targeting the MCM8-MCM9 complex, and further research is needed to fully understand its role in the regulation of protein stability and localization in the cell.
Protein Name: MCM8-MCM9 Complex
The "MCM8-MCM9 complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MCM8-MCM9 complex comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MCM9 | MCMBP | MCMDC2 | MCOLN1 | MCOLN2 | MCOLN3 | MCPH1 | MCPH1-AS1 | MCPH1-DT | MCRIP1 | MCRIP2 | MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8 | MED9 | MEDAG | Mediator Complex | Mediator of RNA Polymerase II Transcription | MEF2A | MEF2B | MEF2C | MEF2C-AS1 | MEF2C-AS2 | MEF2D | MEFV | MEG3 | MEG8 | MEG9 | MEGF10 | MEGF11 | MEGF6 | MEGF8 | MEGF9 | MEI1 | MEI4
